Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients
Future Oncology, our partner journal, has recently published a Short Communication article, which provides details of a real-world study investigating dose modifications of VRd (bortezomib/lenalidomide/dexamethasone) for multiple myeloma patients.
Aims: To evaluate among multiple myeloma (MM) patients, the proportions with first-line (1L) VRd (bortezomib/lenalidomide/dexamethasone) dose modifications and the associated baseline patient characteristics.
Patients and Methods: Adult MM patients treated with 1L VRd were selected from the Optum claims database. VRd dose modifications were defined based on lenalidomide dose.
Results: Among 1,497 MM patients, 33% received VRd lite and 22% VRd reduced. Compared to VRd regular, VRd lite usage was more likely to be associated with patients aged ≥75 years and female sex; VRd reduced usage was more likely to be associated with female sex and frailty.
Conclusions: A large proportion of MM patients received VRd dose modifications in the real-world, which could potentially result in reduced effectiveness of VRd.
